Epidemiological Surveillance of HIV-1 Transmitted Drug Resistance in Spain in 2004-2012: Relevance of Transmission Clusters in the Propagation of Resistance Mutations.
Vega Y, Delgado E, Fernández-García A, Cuevas MT, Thomson MM, Montero V, Sánchez M, Sánchez AM, Pérez-Álvarez L, Spanish Group for the Study of New HIV-1 Diagnoses in Galicia and Basque Country.
PLoS One. 2015; 10. FI: 3.234 (Q1).
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martinez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabie A, Weiss L, Gatell JM, OLE RIS-EST13 Study Grp.
Lancet Infect. Dis. 2015; 15: 785-792. FI: 22.433 (Q1).
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L, D:A:D study group, Royal Free Hospital Clinic Cohort, INSIGHT study group, SMART study group, ESPRIT study group.
PLoS Med. 2015; 12. FI: 14.429 (Q1).
Decreasing prevalence of HCV coinfection in all risk groups for HIV infection between 2004 and 2011 in Spain.
Serrano-Villar S, Sobrino-Vegas P, Monge S, Dronda F, Hernando A, Montero M, Viciana P, Clotet B, Pineda JA, Del Amo J, Moreno S, CoRIS.
J Viral Hepat. 2015; 22: 496-503. FI: 3.909 (Q1).
Current Epidemiology and Outcome of Infective Endocarditis: A Multicenter, Prospective, Cohort Study.
Muñoz P, Kestler M, De Alarcon A, Miro JM, Bermejo J, Rodríguez-Abella H, Fariñas MC, Cobo Belaustegui M, Mestres C, Llinares P, Goenaga M, Navas E, Oteo JA, Tarabini P, Bouza E, Spanish Collaboration on Endocarditis-Grupo de Apoyo al Manejo de la Endocarditi.
Medicine (Baltimore). 2015; 94. FI: 5.723 (Q1).
Comparison of the Prognostic Value of Liver Biopsy and FIB-4 Index in Patients Coinfected With HIV and Hepatitis C Virus.
Berenguer J, Zamora FX, Aldamiz-Echevarria T, Von Wichmann MA, Crespo M, Lopez-Aldeguer J, Carrero A, Montes M, Quereda C, Tellez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Barros C, Ortega E, Pulido F, Rubio R, Mallolas J, Tural C, Jusdado JJ, Perez G, Diez C, Alvarez-Pellicer J, Esteban H, Bellon JM, Gonzalez-Garcia J, SIDA GESIDA HIV HCV Cohort Study.
Clin. Infect. Dis. 2015; 60: 950-958. FI: 8.886 (Q1).
Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA, HIV-CAUSAL Collaboration.
Lancet HIV. 2015; 2. FI: 8.364 (Q1).
Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain.
Estrada V, Bernardino JI, Masia M, Iribarren JA, Ortega A, Lozano F, Miralles C, Olalla J, Santos J, Perez MJ, Domingo P, Fernandez A.
HIV Clin. Trials. 2015; 16: 57-65. FI: 2.629 (Q2).
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.
Clin. Infect. Dis. 2015; 60: 1262-1268. FI: 8.886 (Q1).
Association of baseline CD4+cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients.
Aldamiz-Echevarria T, Gonzalez-Garcia J, Von Wichmann MA, Crespo M, Lopez-Aldeguer J, Quereda C, Tellez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Bellon JM, Montes M, Berenguer J, GESIDA HIV-HCV Cohort Study Grp.
Ann. Hepatol. 2015; 14: 464-469. FI: 2.065 (Q3).
Perfil de seguridad de rilpivirina: tolerabilidad general y neuropsiquiátrica, seguridad en pacientes coinfectados con virus de la hepatitis B/virus de la hepatitis C, y perfil lipídico.
Lopez LF, Martinez E, von Wichmann MA.
Enferm. Infecc. Microbiol. Clin. 2013; 31 (2): 6-11. FI: 1.478 (Q4).
CoRIS. Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class.
Monge S, Guillot V, Álvarez M, Pena A, Viciana P, García-Bujalance S, Pérez Elías MJ, Iribarren JA, Gutiérrez F, Casado MI, García F.
Clin. Microbiol. Infect. 2012; 18: 485-490. FI: 4.540 (Q1).
SINRES Grp. Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens.
Garrido C, Villacian J, Zahonero N, Pattery T, García F, Gutiérrez F, Caballero E, Van Houtte M, Soriano V, De Mendoza C.
Antimicrob. Agents Chemother. 2012; 56: 2873-2878. FI: 4.841 (Q1).
Grp estudio riesgo. Cardiovascular risk in human immunodeficiency virus-infected patients in Spain. CoRIS cohort, 2011.
Masia M, Pérez-Cachafeiro S, Leyes M, López-Aldeguer J, López M, Segura F, Bianco JR, Pena A, Rodríguez F, Vera M, Del Amo J, Gutiérrez F.
Enferm. Infec. Microbiol. Clin. 2012; 30: 517-527. FI: 1.491 (Q3).
